NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01591122,Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT01591122,,COMPLETED,The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).,NO,Prostate Cancer,DRUG: Placebo and prednisone|DRUG: Abiraterone acetate and prednisone,"Time to prostate specific antigen (PSA) progression (TTPP), Measured from the time interval from the date of randomization to the date of the PSA progression based on prostate cancer clinical trials working group 2 (PCWG2) criteria, 14 months","Overall survival, The percentage of people in a study or treatment group who are alive from date of randomization to date of death, 5 years|Time to initiation of cytotoxic chemotherapy, Date of randomization to date of initiation of chemotherapy, 5 years|Prostate specific antigen (PSA) response rate, Proportion of patients achieving a PSA decline 50% according to prostate cancer clinical trials working group 2 (PCWG2) criteria, 14 months|Objective response rate, Measurable disease based on modified response evaluation criteria in solid tumors (RECIST) criteria and baseline lymph node size must be 2.0 cm to be considered target or evaluable lesion for RECIST criteria, 14 months|Quality of life (QoL) total score and each subscale score, Assessed by functional assessment of cancer therapy-prostate (FACT-P), 14 months|Time to pain progression, Assessed by the Brief Pain Inventory Short Form (BPI-SF) and analgesic score, 14 months|Time to Eastern Cooperative Oncology Group (ECOG) performance status score determination, ECOG performance status score 0 (Fully active, able to carry on all pre-disease performance without restriction) versus 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work on a light or sedentary nature, eg, light housework, office work), 14 months|Collection of safety data including adverse events, 5 years",,"Janssen Research & Development, LLC",,MALE,"ADULT, OLDER_ADULT",PHASE3,313,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CR100011|ABI-PRO-3002,2012-03-27,2016-12-31,2019-01-31,2012-05-03,,2020-01-21,"Beijing, China|Chengdu, China|Chongqing, China|Guangzhou, China|Hangzhou, China|Jinan, China|Nanjing, China|Shanghai, China|Tianjin, China|Wuhan, China|Kuala Lumpur N/a, Malaysia|Kuala Lumpur, Malaysia|Arkhangelsk, Russian Federation|Ekaterinburg, Russian Federation|Moscow N/a, Russian Federation|Moscow, Russian Federation|Pyatigorsk, Russian Federation|Rostov-on-Don, Russian Federation|Sochi, Russian Federation|St.-Petersburg, Russian Federation|Stavropol, Russian Federation|Ufa, Russian Federation|Yoshkar-Ola, Russian Federation|Bangkok, Thailand",
